{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:31:15Z","timestamp":1772850675744,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The first-line treatment for Cushing\u2019s disease is transsphenoidal surgery, after which the rates of remission are 60 to 80%, with long-term recurrence of 20 to 30%, even in those with real initial remission. Drug therapies are indicated for patients without initial remission or with surgical contraindications or recurrence, and ketoconazole is one of the main available therapies. The objective of this study was to evaluate the safety profile of and the treatment response to ketoconazole in Cushing\u2019s disease patients followed up at the endocrinology outpatient clinic of a Brazilian university hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This was a retrospective cohort of Cushing\u2019s disease patients with active hypercortisolism who used ketoconazole at any stage of follow-up. Patients who were followed up for less than 7 days, who did not adhere to treatment, or who were lost to follow-up were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 172 Cushing\u2019s disease patients who were followed up between 2004 and 2020, 38 received ketoconazole. However, complete data was only available for 33 of these patients. Of these, 26 (78%) underwent transsphenoidal surgery prior to using ketoconazole, five of whom (15%) had also undergone radiotherapy; seven used ketoconazole as a primary treatment. Ketoconazole use ranged from 14 days to 14.5 years. A total of 22 patients had a complete response (66%), three patients had a partial response (9%), and eight patients had no response to treatment (24%), including those who underwent radiotherapy while using ketoconazole. Patients whose hypercortisolism was controlled or partially controlled with ketoconazole had lower baseline 24-h urinary free cortisol levels than the uncontrolled group [times above the upper limit of normal: 0.62 (SD, 0.41) <jats:italic>vs<\/jats:italic>. 5.3 (SD, 8.21); <jats:italic>p<\/jats:italic> &amp;lt; 0.005, respectively] in addition to more frequent previous transsphenoidal surgery (<jats:italic>p<\/jats:italic> &amp;lt; 0.04). The prevalence of uncontrolled patients remained stable over time (approximately 30%) despite ketoconazole dose adjustments or association with other drugs, which had no significant effect. One patient received adjuvant cabergoline from the beginning of the follow-up, and it was prescribed to nine others due to clinical non-response to ketoconazole alone. Ten patients (30%) reported mild adverse effects, such as nausea, vomiting, dizziness, and loss of appetite. Only four patients had serious adverse effects that warranted discontinuation. There were 20 confirmed episodes of hypokalemia among 10\/33 patients (30%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ketoconazole effectively controlled hypercortisolism in 66% of Cushing\u2019s disease patients, being a relatively safe drug for those without remission after transsphenoidal surgery or whose symptoms must be controlled until a new definitive therapy is carried out. Hypokalemia is a frequent metabolic effect not yet described in other series, which should be monitored during treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1017331","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:30:19Z","timestamp":1665124219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort"],"prefix":"10.3389","volume":"13","author":[{"given":"Camila","family":"Viecceli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina Viana","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carolina Bittencourt","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Borba de","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ticiana da Costa","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro Antonio","family":"Czepielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in cushing\u2019s syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"B2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of cushing\u2019s syndrome: An endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: An endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.10.010","article-title":"Cushing\u2019s syndrome","volume":"37","author":"Pivonello","year":"2008","journal-title":"Endocrinol Metab Clin North"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0539-6","article-title":"Therapeutic strategies for the treatment of severe cushing\u2019s syndrome","volume":"76","author":"Alexandraki","year":"2016","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.20945\/2359-3997000000014","article-title":"A review of cushing\u2019s disease treatment by the department of neuroendocrinology of the Brazilian society of endocrinology and metabolism","volume":"62","author":"Machado","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302007000800022","article-title":"Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing's disease","volume":"51","author":"Rollin","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of cushing\u2019s disease after initial successful transsphenoidal surgery","volume":"93","author":"Patil","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101270","DOI":"10.1016\/j.beem.2019.04.004","article-title":"Therapeutic options after surgical failure in cushing\u2019s disease: A critical review","volume":"33","author":"Rubinstein","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023824","article-title":"Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis","volume":"99","author":"Zhao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3967\/0895-3988.2013.07.013","article-title":"Ketoconazole associated hepatotoxicity: A systematic review and meta-analysis","volume":"26","author":"Yan","year":"2013","journal-title":"Biomed Environ Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in cushing\u2019s disease: Is it worth a try","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.732240","article-title":"N. nogueira, \u201cEffectiveness of medical treatment of cushing\u2019s disease: A systematic review and meta-analysis,\u201d","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in cushing\u2019s syndrome: experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302012000300002","article-title":"Avalia\u00e7\u00e3o do eixo hipot\u00e1lamohip\u00f3fise adrenal no diagn\u00f3stico e na remiss\u00e3o da doen\u00e7a de cushing","author":"Costenaro","year":"2012","journal-title":"Arquivos Brasileiros Endocrinologia e Metabologia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2107","article-title":"Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in cushing\u2019s disease","volume":"100","author":"Amlashi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","volume-title":"Rotinas em endocrinologia","author":"Silveiro","year":"2015"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302011000400008","article-title":"Pseudotumor cerebri during cushing\u2019s disease treatment with ketoconazole","author":"Costenaro","year":"2011","journal-title":"Arq. Bras Endocrinol Metabol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2014.995615","article-title":"A successful case of cushing\u2019s disease pregnancy treated with ketoconazole","volume":"31","author":"Costenaro","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cen.12345","article-title":"Efficacy of medical treatment in cushing\u2019s disease: A systematic review","volume":"80","author":"Gadelha","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-013-1151-1","article-title":"New avenues in the medical treatment of cushing\u2019s disease: Corticotroph tumor targeted therapy","volume":"114","author":"Fleseriu","year":"2013","journal-title":"J Neurooncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0397-5","article-title":"Medical management of cushing\u2019s disease: What is the future","volume":"15","author":"Fleseriu","year":"2012","journal-title":"Pituitary"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for cushing\u2019s disease: Effectiveness of two schedules of treatment. should we start with cabergoline or ketoconazole","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of cushing\u2019s disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: A preoperative or postoperative treatment in cushing\u2019s disease","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-6-1365","article-title":"Use of ketoconazole in the treatment of cushing\u2019s syndrome","volume":"63","author":"Loli","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12442","article-title":"Clinical, biochemical and imaging characteristics of cushing\u2019s macroadenomas and their long-term treatment outcome","volume":"81","author":"Kakade","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170025","article-title":"Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in cushing\u2019s syndrome","volume":"12","author":"Luisetto","year":"2001","journal-title":"Osteoporos Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2015.02.007","article-title":"Assessment of the outcomes of the treatment of cushing\u2019s disease in the hospitals of castilla-la mancha","volume":"62","author":"Huguet","year":"2015","journal-title":"Endocrinol y Nutr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.05.003","article-title":"Advances in the medical treatment of cushing disease","volume":"49","author":"Tritos","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04419.x","article-title":"Association of hypertension and hypokalemia with cushing\u2019s syndrome caused by ectopic ACTH secretion","volume":"970","author":"Torpy","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101490","article-title":"\u201cUpdates in adrenal steroidogenesis inhibitors for cushing\u2019s syndrome \u2013 a practical guide,\u201d","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1017331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:30:23Z","timestamp":1665124223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1017331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":40,"alternative-id":["10.3389\/fendo.2022.1017331"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1017331","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"1017331"}}